The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

A contract for the running of a youth alcohol and other drug rehabilitation centre has been awarded to a Far North ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

In the world of biotechnology, few stories resonate as strongly as that of Pasithea Therapeutics Corp. (NASDAQ: KTTA). On Thursday, the stock saw an impressive surge of +80.31%, reaching $6.90 during ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

By Noah Weiland Noah Weiland has written about the public health policies that seek to address drug overdoses. Drug overdose deaths are decreasing sharply across the country, according to recent ...

After hours: September 24 at 6:34 PM EDT Loading Chart for DRUG ...